Three great shares to buy after this week’s updates?

Do updates make Severn Trent plc (LON: SVT), Alliance Pharma plc (LON: APH) and BHP Billiton plc (LON: BLT) into must-buys?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

We’ve got used to Brexit uncertainty and a lot of folks are more interested in the hot weather than in their investments. But we mustn’t let any of that stop us keeping an eye on the company news coming our way. Here are three that have just released updates, so is it time to buy them?

Super safe dividends

We’ve just had a trading update from Severn Trent (LSE: SVT) whose modest but reliable dividends are much sought after in these Brexit-worry days. In fact, since 23 June, Severn Trent shares have gained 10% to 2,464p, including a modest gain after the latest update.

The water company told us that its cost-cutting plans are “making good progress” and its Water Plus joint venture with United Utilities has completed successfully. Other than that, there’s no real change to expectations for the full year, and the results, due on 24 May, should be in line with expectations.

That suggests we’ll see a modest fall in earnings and a dividend yield of around 3.3%, so should you buy? Well, Severn Trent is a reliable provider of dividends for sure, but with the shares on a P/E as high as 24 now, I think there are better safety bargains out there.

A pharma growth opportunity?

On Tuesday we had a first-half update from Alliance Pharma (LSE: APH) that’s given the shares a 4.5% boost to 45.75p. Alliance’s acquisition of Sinclair Healthcare in December has doubled the firm’s overall sales, with £20.6m from Sinclair contributing to a total of £46.4m,and the integration of the two companies should be pretty much completed by Q3 update time.

Sales of the company’s three main growth products are going as expected too, so there seems to be no problem there. But there was one note of caution regarding the pending Brexit as Alliance tells us it’s “too early to assess the long-term impact.” Yet there are, apparently, no market access issues anticipated, and the fall in Sterling should help Alliance’s bottom line.

Dividends are currently modest at around 3%, but if Alliance Pharma has the ability to grow as many hope, its low P/E of around 11 could make it a bargain.

Mining recovery?

A year-end operational review from BHP Billiton (LSE: BLT) didn’t exactly send the market into rapture, with the shares down 2% to 928p as I write. Production volumes fell across the board, with petroleum output down 6%, copper down 8%, iron ore down 2% and energy coal down 16% (though metallurgical coal output rose 1%). Although production of iron ore in Western Australia hit a new high, the Samarco mine disaster was responsible for the overall fall.

Though this might not look too impressive, the company told us it was mostly ahead of its production guidance, and costs should be in line with expectations and falling. There is, however, going to be a hit of $175m in additional charges for the year, partly due to redundancies and closures, with some impairments in BHP’s coal business.

Despite improving sentiment towards China, that country’s iron ore stockpiles are growing and there are fears that will impact on demand in the coming year, so the sector isn’t yet out of the woods. Long term, BHP could well be a good investment, but it’s hard to quantify now and we might need another year of progress to achieve some clarity.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Caucasian woman with pink her studying from her laptop screen
Investing Articles

New to investing? Here’s Warren Buffett’s strategy for starting from scratch

Warren Buffett says he could find opportunities to earn a 50% annual return in the stock market if he was…

Read more »

Investing Articles

Can the sensational Barclays share price do it all over again in 2026?

Harvey Jones is blown away by what the Barclays share price has been doing lately. Now he looks at whether…

Read more »

Investing Articles

Prediction: in 2026 mega-cheap Diageo shares could turn £10,000 into…

Diageo shares have been burning wealth lately but Harvey Jones says long-suffering investors in the FTSE 100 stock may get…

Read more »

Investing Articles

This overlooked FTSE 100 share massively outperformed Tesla over 5 years!

Tesla has been a great long-term investment, but this lesser-known FTSE 100 company would have been an even better one.

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

I’m backing these 3 value stocks to the hilt – will they rocket in 2026?

Harvey Jones has bought these three FTSE 100 value stocks on three occasions lately, averaging down every time they fall.…

Read more »

Investing Articles

Can the barnstorming Tesco share price do it all over again in 2026?

Harvey Jones is blown away by just how well the Tesco share price has done lately, and asks whether the…

Read more »

Investing Articles

Up 45% in a year with a 7.2% yield and a P/E of 13! Is it too late to buy this fabulous FTSE 250 stock?

Harvey Jones spotted the potential in this ultra-high-yielding FTSE 250 recovery stock, and is thrilled to see it starting to…

Read more »

Investing Articles

What on earth’s going to happen to the BP share price in 2026?

Harvey Jones looks at how the BP share price is shaping up for the year ahead, and finds investors have…

Read more »